SCY-247 — Initial data
Q3 2026
The Company's second-generation antifungal, SCY-247, is currently in a Phase 1 trial of the IV formulation, with data expected in Q3 2026.Source filing
SCYX biotech catalysts & pipeline
SCYNEXIS INC · Data as of 2026-09-08
Upcoming catalysts
SCY-770 — Initial data
H2 2027
A Phase 2 proof-of-concept study of SCY-770 in ADPKD patients is anticipated to begin in Q4 2026 with an early efficacy readout anticipated in the second half of 2027Source filing